PURPOSE: Phase II studies in laryngeal and bladder carcinoma of accelerated radiotherapy with carbogen and nicotinamide (RT+CON) suggested a therapeutic advantage. Therefore, a randomized phase-III trial of RT+CON in locally advanced bladder carcinoma compared to radiotherapy (RT) alone was undertaken. METHODS:One hundred and sixty-five patients with muscle-invasive transitional cell bladder carcinoma were randomized to RT alone and 168 to RT+CON. This paper reports on compliance and toxicity to nicotinamide (NAM) and carbogen and on early radiation-induced adverse bowel and urinary events. RESULTS: Of those receiving RT+CON, 65-69% accepted all doses of NAM. Sixty-four percent of patients presented Grade 1 NAM toxicity (nausea or vomiting), which was severe in 13%. Compliance to carbogen was 85% and none (32 fractions) and 2% (20 fractions) of patients presented severe toxicity. The highest prevalence of severe radiation acute morbidity was seen for urinary frequency (RT: 18% and RT+CON: 15%) and for diarrhea (RT: 3% and RT+CON: 5%). CONCLUSIONS: There is no indication of an increase in radiation-induced morbidity by combining the tumour radiosensitizers carbogen and nicotinamide with radiotherapy. Late morbidity and treatment outcome will ultimately determine if there is a therapeutic benefit.
RCT Entities:
PURPOSE: Phase II studies in laryngeal and bladder carcinoma of accelerated radiotherapy with carbogen and nicotinamide (RT+CON) suggested a therapeutic advantage. Therefore, a randomized phase-III trial of RT+CON in locally advanced bladder carcinoma compared to radiotherapy (RT) alone was undertaken. METHODS: One hundred and sixty-five patients with muscle-invasive transitional cell bladder carcinoma were randomized to RT alone and 168 to RT+CON. This paper reports on compliance and toxicity to nicotinamide (NAM) and carbogen and on early radiation-induced adverse bowel and urinary events. RESULTS: Of those receiving RT+CON, 65-69% accepted all doses of NAM. Sixty-four percent of patients presented Grade 1 NAM toxicity (nausea or vomiting), which was severe in 13%. Compliance to carbogen was 85% and none (32 fractions) and 2% (20 fractions) of patients presented severe toxicity. The highest prevalence of severe radiation acute morbidity was seen for urinary frequency (RT: 18% and RT+CON: 15%) and for diarrhea (RT: 3% and RT+CON: 5%). CONCLUSIONS: There is no indication of an increase in radiation-induced morbidity by combining the tumour radiosensitizers carbogen and nicotinamide with radiotherapy. Late morbidity and treatment outcome will ultimately determine if there is a therapeutic benefit.
Authors: Tanja Langsenlehner; Carmen Döller; Franz Quehenberger; Heidi Stranzl-Lawatsch; Uwe Langsenlehner; Karl Pummer; Karin S Kapp Journal: Strahlenther Onkol Date: 2010-03-26 Impact factor: 3.621
Authors: Kamalakannan Palanichamy; Suman Kanji; Nicolaus Gordon; Krishnan Thirumoorthy; John R Jacob; Kevin T Litzenberg; Disha Patel; Arnab Chakravarti Journal: Clin Cancer Res Date: 2016-11-03 Impact factor: 12.531
Authors: Xu Cao; Srinivasa Rao Allu; Shudong Jiang; Mengyu Jia; Jason R Gunn; Cuiping Yao; Ethan P LaRochelle; Jennifer R Shell; Petr Bruza; David J Gladstone; Lesley A Jarvis; Jie Tian; Sergei A Vinogradov; Brian W Pogue Journal: Nat Commun Date: 2020-01-29 Impact factor: 14.919
Authors: Malcolm Brown; Amélie Rébillard; Nicolas H Hart; Dominic O'Connor; Gillian Prue; Joe M O'Sullivan; Suneil Jain Journal: Sports Med Open Date: 2022-04-08
Authors: Jennifer K Matsui; Haley K Perlow; Alex R Ritter; Rituraj Upadhyay; Raju R Raval; Evan M Thomas; Sasha J Beyer; Clement Pillainayagam; Justin Goranovich; Shirley Ong; Pierre Giglio; Joshua D Palmer Journal: Biomedicines Date: 2022-07-21